EA200700909A1 - Азаиндолкарбоксамиды - Google Patents

Азаиндолкарбоксамиды

Info

Publication number
EA200700909A1
EA200700909A1 EA200700909A EA200700909A EA200700909A1 EA 200700909 A1 EA200700909 A1 EA 200700909A1 EA 200700909 A EA200700909 A EA 200700909A EA 200700909 A EA200700909 A EA 200700909A EA 200700909 A1 EA200700909 A1 EA 200700909A1
Authority
EA
Eurasian Patent Office
Prior art keywords
general formula
disorders
azaindolkarboxamides
ht1a
compounds
Prior art date
Application number
EA200700909A
Other languages
English (en)
Inventor
Петер Гмайнер
Карин Шлоттер
Харальд Хюбнер
Дирк Шмидт
Моника Буххольц
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200700909A1 publication Critical patent/EA200700909A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Данное изобретение относится к производным азаиндолов общей формулыпричем Х представляет собой группу общей формулы X1, какая показана нижеСоединения имеют терапевтический потенциал для лечения заболеваний, которые протекают с нарушениями допаминового обмена и/или нарушениями 5-HT1a-серотонинового переноса сигналов.
EA200700909A 2004-11-12 2005-11-11 Азаиндолкарбоксамиды EA200700909A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004054634A DE102004054634A1 (de) 2004-11-12 2004-11-12 Azaindolcarboxamide
PCT/EP2005/012127 WO2006050976A1 (de) 2004-11-12 2005-11-11 Azaindolcarboxamide

Publications (1)

Publication Number Publication Date
EA200700909A1 true EA200700909A1 (ru) 2007-12-28

Family

ID=35929547

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700909A EA200700909A1 (ru) 2004-11-12 2005-11-11 Азаиндолкарбоксамиды

Country Status (15)

Country Link
US (1) US20070299091A1 (ru)
EP (1) EP1771448A1 (ru)
JP (1) JP2008519797A (ru)
KR (1) KR20070083843A (ru)
CN (1) CN101056878A (ru)
AU (1) AU2005303904A1 (ru)
BR (1) BRPI0517846A (ru)
CA (1) CA2575668A1 (ru)
DE (1) DE102004054634A1 (ru)
EA (1) EA200700909A1 (ru)
IL (1) IL180317A0 (ru)
MX (1) MX2007005649A (ru)
NO (1) NO20072601L (ru)
WO (1) WO2006050976A1 (ru)
ZA (1) ZA200700252B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CA2690789C (en) * 2007-06-15 2014-08-05 Amy Hauck Newman 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
KR20120124428A (ko) 2009-12-30 2012-11-13 아르퀼 인코포레이티드 치환된 피롤로-아미노피리미딘 화합물
MD20140130A2 (ru) 2012-06-29 2015-04-30 Pfizer Inc. Новые 4-(аминозамещенные)-7Н-пирроло[2,3-d]пиримидины в качестве ингибиторов LRRK2
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN106279071B (zh) * 2016-08-10 2019-01-04 广东东阳光药业有限公司 苯基哌嗪衍生物及其使用方法和用途
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
KR20200112910A (ko) 2018-01-26 2020-10-05 시오노기 앤드 컴파니, 리미티드 도파민 d3 수용체 길항 작용을 갖는 축환 화합물
CA3111785A1 (en) 2018-09-11 2020-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3 receptor selective antagonists/partial agonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340113C (en) * 1988-05-24 1998-11-03 Magid A. Abou-Gharbia Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
HUT71799A (en) * 1993-03-01 1996-02-28 Merck Sharp & Dohme Pyrrolo-pyridine derivatives, pharmaceutical compositions containing the same, process for producing them
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
CN1665503A (zh) * 2002-07-04 2005-09-07 施瓦茨制药有限公司 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途
AU2003267201B2 (en) * 2002-09-14 2009-04-23 The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Structurally rigid dopamine D3 receptor selective ligands and process for making them
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
CA2525502C (en) * 2003-05-21 2012-12-18 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
SE0401655D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
CN101056878A (zh) 2007-10-17
EP1771448A1 (de) 2007-04-11
IL180317A0 (en) 2007-06-03
NO20072601L (no) 2007-05-22
JP2008519797A (ja) 2008-06-12
BRPI0517846A (pt) 2008-10-21
ZA200700252B (en) 2009-05-27
CA2575668A1 (en) 2006-05-18
AU2005303904A1 (en) 2006-05-18
DE102004054634A1 (de) 2006-05-18
US20070299091A1 (en) 2007-12-27
MX2007005649A (es) 2007-07-09
KR20070083843A (ko) 2007-08-24
WO2006050976A1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
EA200700909A1 (ru) Азаиндолкарбоксамиды
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
UY28473A1 (es) Nuevos compuestos
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
SE0303180D0 (sv) Novel compounds
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
EA200802054A1 (ru) Ингибиторы фермента
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
EA201001414A1 (ru) Производные азетидина и их применение
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA200700707A1 (ru) Производные 2-ациламинотиазола